Nuformix PLC Appointment of Dr Karl Keegan (2813D)
February 18 2020 - 2:00AM
UK Regulatory
TIDMNFX
RNS Number : 2813D
Nuformix PLC
18 February 2020
18 February 2020
Nuformix plc
("Nuformix" or "the Company")
Appointment of Dr Karl Keegan
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs today announces the appointment of Dr Karl Keegan to
the Board of Nuformix as a Non-Executive Director with immediate
effect.
Karl has over 25 years of experience working in senior roles in
the life sciences industry. He is currently Chief Executive Officer
and Executive Board member at HOX Therapeutics Ltd, a private
biotechnology company developing first-in-class, highly targeted
cancer therapies based on HOX genes.
Karl spent 12 years as a highly regarded sell-side life sciences
research analyst, researching and helping finance companies across
the UK, Europe, USA and Canada. Since then, primarily in CFO roles,
he has focused on corporate development, and has a successful track
record of devising and implementing M&A and finance projects,
delivering value across all aspects of business strategy,
highlights include the sale of Minster pharmaceuticals plc to
Proximagen plc, multiple financings to support a new strategy for
Pharming Group NV and leadership of M&A deals at Vectura Group
plc.
Karl graduated from University College Dublin, Ireland in 1988
with a B.Sc. in Pharmacology and gained M.Phil. and Ph.D. degrees
(Pharmacology) from the University of Cambridge (UK) where he was
funded by a Parke-Davis Research Scholarship. Following
postdoctoral work at Baylor College of Medicine, Houston Texas, as
a Society of Epilepsy Young Investigator, he worked at SmithKline
Beecham PLC in both research and in Strategic Product Development
for the Neuroscience therapy area. In 2005 he completed a M.Sc. in
Finance at the London Business School, focussing on entrepreneurial
finance and valuation of early stage businesses.
Dr Dan Gooding, Chief Executive Officer of Nuformix Plc,
commented: "I am delighted to welcome Karl to the Nuformix Board.
With his extensive experience in strategy, finance, corporate
development and capital markets within life sciences, Karl brings a
wealth of experience that is highly relevant to Nuformix at this
moment as we enter new stages in the development of the Company and
our assets."
The Company has entered into an agreement with Karl whereby Karl
will be issued with warrants to subscribe for 3,000,000 new
ordinary shares of 0.1 pence in the capital of the Company
conditional upon Karl continuing to act as Non-executive director
of the Company on 17 February 2021 ("Warrants"). The Warrants are
exercisable from 17 February 2021 to 17 February 2023, at an
exercise price of 6.75 pence per ordinary share.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer
Email: info@nuformix.com +44 (0)1223 627222
Novum Securities Limited
Jon Belliss / Colin Rowbury +44 (0)20 7399 9427
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUBSORRKUUAUR
(END) Dow Jones Newswires
February 18, 2020 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024